Ionis Pharma’s Dawnzera received FDA approval as a preventive therapy for hereditary angioedema attacks, entering a competitive market dominated by Takeda’s existing medication. Clinical data suggest patients switching to Dawnzera experience improved outcomes, positioning Ionis to capture market share in this rare disease segment.